US5523088A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Inactivated avian polyomavirus vaccine in psittacine birds
Assignee: University of Georgia Research Foundation Inc
•
Filing: 1994-01-13
•
Granted: 1996-06-04
•
Expires: 2014-01-13
Abstract
Abstract The present invention provides a vaccine which is protective against avian polyomavirus infection in a bird which is classified as being a member of the Psittaciformes order which comprises an immunogenic amount of an inactivated avian polyomavirus in a pharmaceutically acceptable carrier. Also provided is an adjuvant suitable for use in a bird which is classified as being a member of the Psittaciformes order. Further provided is a composition which produces an anamnestic response against avian polyomavirus infection in a sensitized bird which is classified as being a member of the Psittaciformes order, which comprises an anamnestic response inducing amount of a recombinant protein (e.g., VP1 capsid protein) of avian polyomavirus in a pharmaceutically acceptable carrier. Methods are also provided for preventing avian polyomavirus infection in a bird, or in several different species of birds, classified as being a member of the Psittaciformes order, comprising administering a vaccine comprising an immunogenic amount of an inactivated avian polyomavirus and a pharmaceutically acceptable carrier.
Inventors
- 👤 Branson W. Ritchie
- 👤 Frank D. Niagro
- 👤 Kenneth S. Latimer
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-03 10:03
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/005; A; A61; A61K; A61K38/00; C12; C12N; C12N2710/00; C12N2710/00011; C12N2710/22011; C12N2710/22022; Y; Y02; Y02A; Y02A50/00; Y02A50/30; Y10; Y10S; Y10S424/00; Y10S424/816
Claims Analysis
Total Claims: 17
Claim 1
Independent Claim
86 words
A vaccine which is protective against avian polyomavirus infection in a bird which is classified as being a member of the Psittaciformes order, comprising: a) an immunogenic amount of an inactivated avian polyomavirus, wherein the immunogenic amount of the inactivated avian polyomavirus corresponds to a titer of at least 10 4 .5 TCID 50 for the avian polyomavirus before inactivation; b) an adjuvant suitable for use in a bird which is classified as being a member of the Psittaciformes order; and c) a pharmaceutically acceptable carrier.
Claim 2
Dependent Claim
86 words
A vaccine which is protective against avian polyomavirus infection in a bird which is classified as being a member of the Psittaciformes order, comprising: a) an immunogenic amount of an inactivated avian polyomavirus, wherein the immunogenic amount of the inactivated avian polyomavirus corresponds to a titer of at least 10 4 .5 TCID 50 for the avian polyomavirus before inactivation; b) an adjuvant suitable for use in a bird which is classified as being a member of the Psittaciformes order; and c) a pharmaceutically acceptable carrier.
Claim 3
Dependent Claim
22 words
The vaccine of claim 1, wherein the adjuvant is a long chain polydispersed β (1,4) linked mannan polymer interspersed with O-acetylated groups.
Claim 4
Dependent Claim
24 words
The vaccine of claim 1, wherein the adjuvant is a deproteinized highly purified cell wall extract derived from a non-pathogenic strain of Mycobacterium species.
Claim 5
Dependent Claim
10 words
The vaccine of claim 2, wherein the adjuvant is ACEMANNAN.
Claim 6
Dependent Claim
31 words
The vaccine of claim 1, wherein the immunogenic amount of the inactivated avian polyomavirus corresponds to a titer of about 10 5 .8 TCID 50 for the avian polyomavirus before inactivation.
Claim 7
Dependent Claim
32 words
The vaccine of claim 1, wherein the bird is selected from the group consisting of a macaw, an Amazon parrot, a conure, a cockatoo, a Pionus Parrot, and an African Grey Parrot.
Claim 8
Independent Claim
63 words
A method of preventing avian polyomavirus infection in a bird which is classified as being a member of the Psittaciformes order, comprising administering to the bird a vaccine comprising: a) an immunogenic amount of an inactivated avian polyomavirus; b) an adjuvant suitable for use in a bird which is classified as a member of the Psittaciformes order; and c) a pharmaceutically acceptable carrier.
Claim 9
Independent Claim
63 words
A method of preventing avian polyomavirus infection in a bird which is classified as being a member of the Psittaciformes order, comprising administering to the bird a vaccine comprising: a) an immunogenic amount of an inactivated avian polyomavirus; b) an adjuvant suitable for use in a bird which is classified as a member of the Psittaciformes order; and c) a pharmaceutically acceptable carrier.
Claim 10
Dependent Claim
22 words
The method of claim 7, wherein the adjuvant is a long chain polydispersed β (1,4) linked mannan polymer interspersed with O-acetylated groups.
Claim 11
Dependent Claim
24 words
The method of claim 7, wherein the adjuvant is a deproteinized highly purified cell wall extract derived from a non-pathogenic strain of Mycobacterium species.
Claim 12
Dependent Claim
10 words
The method of claim 8, wherein the adjuvant is ACEMANNAN.
Claim 13
Dependent Claim
36 words
The method of claim 7, wherein the immunogenic amount of the inactivated avian polyomavirus corresponds to a titer of between 10 4 .5 TCID 50 and 10 7 TCID 50 for the avian polyomavirus before inactivation.
Claim 14
Dependent Claim
30 words
The method of claim 7, wherein the immunogenic amount of the inactivated avian polyomavirus corresponds to a titer of 10 5 .8 TCID 50 for the avian polyomavirus before inactivation.
Claim 15
Dependent Claim
32 words
The method of claim 7, wherein the bird is selected from the group consisting of a macaw, an Amazon parrot, a conure, a cockatoo, a Pionus Parrot, and an African Grey Parrot.
Claim 16
Independent Claim
75 words
A method of preventing avian polyomavirus infection in a bird which is classified as being a member of the Psittaciformes order, comprising administering to the bird a vaccine comprising: a) an immunogenic amount of an inactivated avian polyomavirus which infects a bird from a different species of the Psittaciformes order; b) an adjuvant suitable for use in a bird which is classified as a member of the Psittaciformes order; and c) a pharmaceutically acceptable carrier.
Claim 17
Independent Claim
75 words
A method of preventing avian polyomavirus infection in a bird which is classified as being a member of the Psittaciformes order, comprising administering to the bird a vaccine comprising: a) an immunogenic amount of an inactivated avian polyomavirus which infects a bird from a different species of the Psittaciformes order; b) an adjuvant suitable for use in a bird which is classified as a member of the Psittaciformes order; and c) a pharmaceutically acceptable carrier.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1999-06-04 | 1999-12-04 | 2000-06-04 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2003-06-04 | 2003-12-04 | 2004-06-04 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2007-06-04 | 2007-12-04 | 2008-06-04 | $7700.00 | Window Closed / Lapsed |